The field of gene therapy continues to advance rapidly, offering hope to patients with rare and devastating genetic disorders. However, progress is often accompanied by regulatory scrutiny and careful reassessment of safety data. In January 2026, REGENXBIO Inc. announced a significant regulatory development involving two of its investigational gene therapies, RGX-111 and RGX-121, both designed to treat ultra rare lysosomal storage disorders known as mucopolysaccharidosis type I and type II.
Following a preliminary safety signal observed in a long term clinical study, the U.S. Food and Drug Administration placed a clinical hold on both programs. This decision has generated attention across the biotechnology, rare disease, and patient advocacy communities, particularly given the urgent unmet medical needs associated with these conditions.
This article explains what the FDA clinical hold means, outlines the details of the reported safety event, and explores the broader implications for gene therapy development in rare pediatric diseases.
Mucopolysaccharidoses, often abbreviated as MPS, are a group of inherited metabolic disorders caused by deficiencies in enzymes responsible for breaking down glycosaminoglycans. These complex sugar molecules accumulate in cells and tissues, leading to progressive damage to organs, bones, and the central nervous system.
MPS I is an autosomal recessive disorder caused by a deficiency in the enzyme alpha L iduronidase. The most severe form, Hurler syndrome, presents in infancy or early childhood and can lead to developmental delay, cognitive impairment, spinal cord compression, and early mortality if untreated.
Current disease modifying treatments include hematopoietic stem cell transplantation and enzyme replacement therapy. While these approaches can improve survival and somatic symptoms, they do not reliably address neurological decline due to limited penetration across the blood brain barrier.
MPS II is an X linked recessive condition that primarily affects boys. It results from a deficiency in iduronate 2 sulfatase, leading to the accumulation of heparan sulfate in tissues, including the brain. Severe forms of MPS II are associated with early developmental delays and progressive neurocognitive decline.
Despite advances in enzyme replacement therapy, there remains no widely available treatment that effectively targets central nervous system involvement in MPS II. This gap has driven interest in gene therapies that deliver corrective genes directly to the brain.
REGENXBIO has been a pioneer in adeno associated virus based gene therapy since its founding in 2009. Both RGX-111 and RGX-121 use AAV vectors to deliver functional genes into the central nervous system via intracisternal administration.
RGX-111 is designed to deliver the IDUA gene using an AAV9 vector. By enabling long term expression of alpha L iduronidase in the brain, the therapy aims to prevent or slow cognitive decline in children with MPS I.
RGX-111 has received orphan drug, rare pediatric disease, and Fast Track designations from the FDA, highlighting its potential importance in addressing a serious unmet need.
RGX-121, also known as clemidsogene lanparvovec, delivers the IDS gene to the central nervous system. The expressed protein is structurally identical to normal iduronate 2 sulfatase, allowing for long term enzymatic activity beyond the blood brain barrier.
RGX-121 has received multiple regulatory recognitions, including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy designations in the United States, as well as advanced therapy medicinal product classification in Europe.
On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 following the identification of a serious adverse event in its Phase I II study. The FDA also extended the hold to RGX-121 due to similarities in the products, study populations, and potential shared risks.
The safety signal involved a single case of neoplasm, specifically an intraventricular central nervous system tumor, detected during routine MRI screening. The participant was an asymptomatic five year old who had received RGX-111 via intracisternal administration approximately four years earlier.
Preliminary genetic analysis of the resected tumor revealed an AAV vector genome integration event associated with overexpression of a proto oncogene known as PLAG1. This gene is recognized for its susceptibility to chromosomal rearrangements in certain tumor types.
Importantly, the investigation into whether the tumor is related to the gene therapy remains ongoing, and causality has not been established.
According to REGENXBIO, the child remains asymptomatic and continues to show positive developmental progress as reported by the treating physician. The tumor was detected early during routine imaging rather than due to clinical symptoms.
No evidence of neoplasm has been reported in the nine other participants treated with RGX-111 or in the 32 participants who received RGX-121, including individuals dosed nearly seven years ago.
REGENXBIO leadership expressed surprise at the FDA decision to place RGX-121 on hold while the investigation of the RGX-111 case continues. The company emphasized that the two therapies are distinct programs and highlighted the favorable long term safety data observed in RGX-121 trials.
The company reiterated that patient safety remains its highest priority and noted confidence in the benefit risk profile of RGX-121, particularly given the devastating and progressive nature of untreated MPS II.
REGENXBIO has stated that it has not yet received the full clinical hold letter from the FDA and is awaiting additional details to guide next steps.
A clinical hold is a regulatory action that temporarily pauses clinical trial enrollment and dosing. It allows regulators and sponsors to review safety data and determine whether protocol modifications, additional monitoring, or further preclinical studies are necessary.
For patients and families affected by ultra rare diseases, clinical holds can be emotionally challenging. Delays in development may translate into continued neurodevelopmental decline, especially in disorders where early intervention is critical.
However, clinical holds also reflect the cautious approach required when developing therapies that permanently alter genetic material, particularly in pediatric populations.
This case highlights ongoing questions around AAV vector integration and long term oncogenic risk. While AAV vectors are generally considered non integrating, rare integration events have been documented, and their clinical significance continues to be studied.
Regulatory agencies worldwide are increasingly focused on long term follow up and post treatment surveillance for gene therapy recipients. Events like this reinforce the importance of routine imaging, genetic analysis, and transparent reporting.
The outcome of the FDA investigation may influence future trial designs, risk mitigation strategies, and regulatory expectations for central nervous system directed gene therapies.
Despite this setback, the gene therapy field remains optimistic. Thousands of patients have already been treated with therapies developed using REGENXBIO’s AAV platform, including approved treatments such as ZOLGENSMA.
For MPS I and MPS II, the need for therapies that address neurological disease remains urgent. Whether RGX-111 and RGX-121 resume clinical development will depend on the FDA’s assessment of causality, risk mitigation options, and overall benefit risk balance.
Patient advocacy groups, clinicians, and researchers will be watching closely as more information becomes available.
The FDA clinical hold on RGX-111 and RGX-121 underscores both the promise and complexity of gene therapy for ultra rare pediatric diseases. While a single inconclusive safety event has prompted regulatory caution, the broader body of clinical data continues to suggest potential for meaningful benefit.
As investigations proceed, transparency and collaboration between regulators, developers, clinicians, and patient communities will be essential. For families affected by MPS I and MPS II, the hope for transformative treatments remains strong, even as safety considerations take center stage.
REGENXBIO Inc. press release, January 28, 2026.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Clinical trial data and regulatory decisions may change as additional information becomes available. Patients and caregivers should consult qualified healthcare professionals regarding medical conditions and treatment options.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.